SUMMARY Studies in 14 patients with unconjugated hyperbilirubinaemia caused by Gilbert's syndrome have revealed abnormalities of the enzymes of haem biosynthesis measured in peripheral blood cells. The activity of the penultimate enzyme of haem biosynthesis protoporphyrinogen (PROTO) oxidase was reduced at 3-1±2.6 nmol PROTO/g protein/h (mean±ISD) compared with 8*2±5-1 in controls (p<0.005). This was associated with a compensatory increase in the activity of the initial and rate controlling enzyme of the pathway delta-aminolaevulinic acid (ALA) synthase at 866±636 nmol ALA/g/protein/h compared with 156±63 in controls (p<0.001). Unlike variegate porphyria in which there is a genetic deficiency of PROTO oxidase there was no increased excretion of porphyrins or their precursors in Gilbert's syndrome. Accentuation and subsequent correction of the unconjugated hyperbilirubinaemia with rifampicin produced reciprocal changes in PROTO oxidase activity indicating that bilirubin may be inhibiting the activity of this enzyme.
ferase activity.`8 Gilbert's syndrome may be a heterogenous disorder. 9 We wish to report a previously unrecognised biochemical abnormality in patients with the syndrome which involves the enzymes of haem biosynthesis and discuss its relationship to the previously reported disturbances in haem degradation.
Methods

PATI ENTS
Eleven male and three female patients previously diagnosed to have Gilbert's syndrome were studied. Their mean age was 33 years (range 19-59). Total bilirubin concentrations at the time studied ranged from 19-54 [imol/l (normal range [5] [6] [7] [8] [9] [10] [11] [12] [13] [14] [15] [16] [17] with a mean value of 31 I,mol/l. In each case the bilirubin was predominantly unconjugated and the reticulocyte count less than 2%. None of the patients was on any medication. For comparison, 20 normal subjects (15 men and five women, mean age 32 years) and nine patients with variegate porphyria (eight women and one man, mean age 31 years) were also studied. Each of the porphyria patients had experienced an attack 125 of porphyria in the past but were all in clinical remission when studied. The diagnosis of variegate porphyria had been confirmed previously by markedly increased faecal porphyrin excretion, consisting predominantly of protoporphyrin, together with increased urinary excretion of ALA and porphobilinogen.
In six of the subjects with Gilbert's syndrome, the effect of rifampicin on the serum bilirubin concentration and activities of leucocyte ALA synthase and PROTO oxidase was studied. It was administered in single daily doses of 600 mg at 23 00 hours and blood samples for bilirubin and rifampicin concentrations and enzyme activities obtained nine hours after the second, seventh and 10th doses. In one subject it was not possible to obtain the two later samples. . gate porphyria had increased faecal excretion of protoporphyrin and coproporphyrin and in five there was also increased excretion of ALA and porphobilinogen in the urine ( Table 2 ). The erythrocyte protoporphyrin concentration was normal in both conditions. Rifampicin treatment in each of the six patients studied with Gilbert's syndrome initially increased the total bilirubin concentration because of a rise in the unconjugated fraction (Fig. 3) . Nine hours after g. 
Discussion
Our observations indicate that in addition to disturbed bilirubin metabolism subjects with Gilbert's syndrome also have abnormalities of haem biosynthesis characterised by increased activity of the initial enzyme of the pathway ALA synthase and reduced activity of the penultimate enzyme PROTO oxidase. Delta-aminolaevulinic acid synthase is the rate controlling enzyme of haem biosynthesis and under negative feedback control by haem. In the acute porphyrias in which there are genetic deficiencies of individual enzymes in the pathway -for example, PROTO oxidase in variegate porphyria, there is a compensatory increase in ALA synthase activity. In Gilbert's syndrome the increased ALA synthase activity can be explained by the reduced PROTO oxidase activity. The biphasic effect of rifampicin on the unconjugated bilirubin concentration allowed the relationship of the abnormal haem biosynthesis and hyperbilirubinaemia to be examined. The initial rise in the unconjugated bilirubin concentration on starting rifampicin, which is most marked nine hours after each dose, is because of competition for hepatic uptake, and the subsequent normalisation of the bilirubin level, and fall in the serum drug level, because of the induction of this process.'617 The reciprocal changes in PROTO oxidase activity suggest that the enzyme is being inhibited by unconjugated bilirubin. The preliminary studies excluded the possibility that the decreased PROTO oxidase activity was artefactual because of bilirubin or rifampicin interfering with the measurement of its activity and the increased ALA synthase activity confirms an in vivo block in haem biosynthesis. The changes in ALA synthase activity with rifampicin therapy are also consistent with unconjugated bilirubin impeding the rate of haem synthesis. The initial increase in ALA synthase activity on rifampicin, however, may also be explained by the haemoprotein inducing effects of the drug. '8 Bilirubin IXai is structurally very similar to protoporphyrinogen, the normal substrate of PROTO oxidase, and may be acting as a competitive inhibitor. It has been shown in vitro to inhibit the enzyme ferrochelatase which has protoporphyrin as its substrate.'9 Unfortunately, no purified preparations of PROTO oxidase are currently available for satisfactory in vitro inhibitory studies. If hyperbilirubinaemia is responsible for the decreased PROTO oxidase activity in Gilbert's syndrome, a significant negative correlation of the two might have been expected. Two reasons may account for the absence of this. Firstly, it is likely to be the unconjugated and unbound fraction of bilirubin which will inhibit the enzyme and currently there is no satisfactory assay for accurately measuring this, and secondly there may not be a direct linear correlation between the concentration of bilirubin in the serum and its concentration in the vicinity of the enzyme PROTO oxidase which is sited on the inner mitochondrial membrane.
If subjects with Gilbert's syndrome have an enzymatic defect similar to variegate porphyria they might be expected to have increased porphyrin excretion. This does not invariably follow, however, as a proportion of patients with variegate porphyria have normal porphyrin excretion when asymptomatic.20The tissue in which the enzyme abnormalities are present is also important. In the porphyrias, the enzyme defect is thought to be present in all cells though the porphyrin overproduction is mainly hepatic in origin.2' In Gilbert's syndrome the enzyme defect has been shown in peripheral leucocytes and we have no information regarding haem biosynthesis in the liver. If the impaired haem biosynthesis in Gilbert's syndrome is the result of the unconjugated hyperbilirubinaemia and Gilbert's syndrome is because of impaired hepatic uptake of unconjugated bilirubin, then intrahepatic haem biosynthesis would be spared and there would be no increased porphyrin excretion because of hepatic overproduction.
Abnormalities of porphyrin excretion do occur in the Dubin-Johnson syndrome and Rotor's syndrome in which the hereditary defects in hepatic bilirubin handling involve hepatocellular excretion rather than uptake or conjugation of the pigment,' I and also in obstructive jaundice.24 In 1981, Evans et all reported a patient with conjugated hyperbilirubinaemia resembling that seen in Rotor's syndrome, who also had unexplained increased faecal porphyrin excretion typical of variegate porphyria. Though some of these porphyrin abnormalities associated with conjugated hyperbilirubinaemia can be explained by impaired hepatic porphyrin excretion, abnormal hepatic porphyrin synthesis caused by increased hepatocellular bilirubin concentrations may also be important.
